Search

Search Constraints

You searched for: Author/Creator Colen, Rivka

Search Results

12. NIMG-29. ASSOCIATION OF PARTIAL T2-FLAIR MISMATCH SIGN AND ISOCITRATE DEHYDROGENASE MUTATION IN WHO GRADE 4 GLIOMA/GLIOBLASTOMA: RESULTS FROM THE RESPOND CONSORTIUM. (14th November 2022)

13. NIMG-33. PROGNOSTIC STRATIFICATION OF DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: UPDATES FROM THE RESPOND CONSORTIUM. (14th November 2022)

14. NIMG-40. ROBUST MODALITY-AGNOSTIC SKULL-STRIPPING IN PRESENCE OF DIFFUSE GLIOMA: A MULTI-INSTITUTIONAL STUDY. (11th November 2019)

15. NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1, 458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS. Issue 11 (6th November 2017)

16. NIMG-66. AI-BASED PROGNOSTIC IMAGING BIOMARKERS FOR PRECISION NEUROONCOLOGY AND THE RESPOND CONSORTIUM. (9th November 2020)

17. NIMG-67. MULTI-PARAMETRIC MRI-BASED MACHINE LEARNING ANALYSIS FOR PREDICTION OF NEOPLASTIC INFILTRATION AND RECURRENCE IN PATIENTS WITH GLIOBLASTOMA: UPDATES FROM THE MULTI-INSTITUTIONAL RESPOND CONSORTIUM. (14th November 2022)

18. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Issue 8 (10th March 2020)

19. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Issue 9 (5th April 2018)

20. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Issue 4 (22nd November 2019)